These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 30999281)

  • 21. [
    Yang T; Chen C; Pan NF; Sun LY; Jiang XL; Li JN; Tang Y; Jiang Y
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 Dec; 50(6):919-924. PubMed ID: 31880125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF
    Nasirden A; Saito T; Fukumura Y; Hara K; Akaike K; Kurisaki-Arakawa A; Asahina M; Yamashita A; Tomomasa R; Hayashi T; Arakawa A; Yao T
    Virchows Arch; 2016 Dec; 469(6):687-696. PubMed ID: 27718012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metastatic-prone telomerase reverse transcriptase (TERT) promoter and v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutated tall cell variant of papillary thyroid carcinoma arising in ectopic thyroid tissue: A case report.
    Stenman A; Koman A; Ihre-Lundgren C; Juhlin CC
    Medicine (Baltimore); 2021 Jan; 100(2):e24237. PubMed ID: 33466206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients.
    Jin L; Chen E; Dong S; Cai Y; Zhang X; Zhou Y; Zeng R; Yang F; Pan C; Liu Y; Wu W; Xing M; Zhang X; Wang O
    Oncotarget; 2016 Apr; 7(14):18346-55. PubMed ID: 26943032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRAF-induced EHF expression affects TERT in aggressive papillary thyroid cancer.
    Xu Y; Gao J; Wang N; Zedenius J; Nilsson IL; Lui WO; Xu D; Juhlin CC; Larsson C; Mu N
    J Clin Endocrinol Metab; 2024 Aug; ():. PubMed ID: 39183149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of TERT promoter and BRAF mutations in TIR-4 and TIR-5 thyroid cytology.
    Censi S; Barollo S; Grespan E; Watutantrige-Fernando S; Manso J; Iacobone M; Casal Ide E; Galuppini F; Fassina A; Bertazza L; Vianello F; Pennelli G; Mian C
    Eur J Endocrinol; 2019 Jul; 181(1):1-11. PubMed ID: 31042674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncogenic Properties of the Antisense lncRNA
    Esposito R; Esposito D; Pallante P; Fusco A; Ciccodicola A; Costa V
    Cancer Res; 2019 May; 79(9):2124-2135. PubMed ID: 30862713
    [No Abstract]   [Full Text] [Related]  

  • 28. E26 transformation (ETS)‑specific related transcription factor‑3 (ELF3) orchestrates a positive feedback loop that constitutively activates the MAPK/Erk pathway to drive thyroid cancer.
    Chen H; Chen W; Zhang X; Hu L; Tang G; Kong J; Wang Z
    Oncol Rep; 2019 Jan; 41(1):570-578. PubMed ID: 30365150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-A meta-analysis.
    Vuong HG; Altibi AMA; Duong UNP; Hassell L
    Clin Endocrinol (Oxf); 2017 Nov; 87(5):411-417. PubMed ID: 28666074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation.
    Cao YM; Gu J; Zhang YS; Wei WJ; Qu N; Wen D; Liao T; Shi RL; Zhang L; Ji QH; Wang Y; Sun GH; Zhao YX; Wang YJ; Yu J; Zhu YX
    Oncol Rep; 2018 Jan; 39(1):338-348. PubMed ID: 29115628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A six-genotype genetic prognostic model for papillary thyroid cancer.
    Shen X; Liu R; Xing M
    Endocr Relat Cancer; 2017 Jan; 24(1):41-52. PubMed ID: 27875244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tall cell papillary thyroid carcinoma: new diagnostic criteria and mutations in BRAF and TERT.
    Dettmer MS; Schmitt A; Steinert H; Capper D; Moch H; Komminoth P; Perren A
    Endocr Relat Cancer; 2015 Jun; 22(3):419-29. PubMed ID: 25870252
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ETS Factor ETV5 Activates the Mutant Telomerase Reverse Transcriptase Promoter in Thyroid Cancer.
    Bullock M; Lim G; Zhu Y; Åberg H; Kurdyukov S; Clifton-Bligh R
    Thyroid; 2019 Nov; 29(11):1623-1633. PubMed ID: 31452441
    [No Abstract]   [Full Text] [Related]  

  • 34. Frequent BRAF
    Oishi N; Kondo T; Nakazawa T; Mochizuki K; Inoue T; Kasai K; Tahara I; Yabuta T; Hirokawa M; Miyauchi A; Katoh R
    Endocr Pathol; 2017 Jun; 28(2):103-111. PubMed ID: 28176151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DUSP5 and DUSP6, two ERK specific phosphatases, are markers of a higher MAPK signaling activation in BRAF mutated thyroid cancers.
    Buffet C; Hecale-Perlemoine K; Bricaire L; Dumont F; Baudry C; Tissier F; Bertherat J; Cochand-Priollet B; Raffin-Sanson ML; Cormier F; Groussin L
    PLoS One; 2017; 12(9):e0184861. PubMed ID: 28910386
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TERT Promoter Mutations and Tumor Persistence/Recurrence in Papillary Thyroid Cancer.
    Myung JK; Kwak BK; Lim JA; Lee MC; Kim MJ
    Cancer Res Treat; 2016 Jul; 48(3):942-7. PubMed ID: 26727717
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma.
    Bournaud C; Descotes F; Decaussin-Petrucci M; Berthiller J; de la Fouchardière C; Giraudet AL; Bertholon-Gregoire M; Robinson P; Lifante JC; Lopez J; Borson-Chazot F
    Eur J Cancer; 2019 Feb; 108():41-49. PubMed ID: 30648628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Telomerase reverse transcriptase mutations are independent predictor of disease-free survival in Middle Eastern papillary thyroid cancer.
    Bu R; Siraj AK; Divya SP; Kong Y; Parvathareddy SK; Al-Rasheed M; Al-Obaisi KAS; Victoria IG; Al-Sobhi SS; Al-Dawish M; Al-Dayel F; Al-Kuraya KS
    Int J Cancer; 2018 May; 142(10):2028-2039. PubMed ID: 29266240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BRAFV600E mutation, TIMP-1 upregulation, and NF-κB activation: closing the loop on the papillary thyroid cancer trilogy.
    Bommarito A; Richiusa P; Carissimi E; Pizzolanti G; Rodolico V; Zito G; Criscimanna A; Di Blasi F; Pitrone M; Zerilli M; Amato MC; Spinelli G; Carina V; Modica G; Latteri MA; Galluzzo A; Giordano C
    Endocr Relat Cancer; 2011 Dec; 18(6):669-85. PubMed ID: 21903858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TERT promoter mutations and Ki-67 labeling index as a prognostic marker of papillary thyroid carcinomas: combination of two independent factors.
    Matsuse M; Yabuta T; Saenko V; Hirokawa M; Nishihara E; Suzuki K; Yamashita S; Miyauchi A; Mitsutake N
    Sci Rep; 2017 Feb; 7():41752. PubMed ID: 28150740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.